Skip to Main Content

The two former Kite Pharma executives behind a game-changing cancer-killing technology are launching their next act: a new company to develop a suite of so-called off-the-shelf CAR-T therapy assets, designed so that they do not need to be personalized for each cancer patient.

Allogene Therapeutics, which was unveiled Tuesday morning, has raised $300 million to acquire and advance a portfolio of experimental cell therapies previously controlled by Pfizer. As a consequence of the deal, Pfizer is getting out of the business of being a major CAR-T player, though it will take a 25 percent ownership stake in Allogene.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Could off the shelf Car-T cell technology also be developed for solid tumors?

  • If this new treatment does not require chemo before the new cells were infused that would be a real breakthrough possibly eliminating the horrendous side affects caused by chemo.

Comments are closed.